Viemed Healthcare projects significant revenue and EBITDA growth for 2025, with EPS expected to rise by 42.86% in 2025. Read why VMD stock is a Buy.
Viemed Healthcare: Remaining Bullish Due To Strong Forward-Looking EPS Revisions
view original post